Nanoscope's MCO-010 Shows Notable Improvement in Vision Function for Stargardt Disease

Nanoscope Therapeutics announced significant findings from its Phase 2 clinical trial, STARLIGHT, during the annual meeting of the American Society of Retina Specialists (ASRS) in Seattle last week. The trial centered on assessing the impact of their innovative therapeutic, MCO-010, on patients with Stargardt disease, a condition currently devoid of available treatments.

Key Highlights from the STARLIGHT Clinical Trial:

● Patients administered with MCO-010 exhibited noteworthy improvements in best-corrected visual acuity (BCVA).

● An estimated gain of around 3 dB was recorded in mean sensitivity, as evaluated by Octopus visual field perimetry.

● Notably, no instances of serious adverse events (SAEs) were detected among patients who received MCO-010 in the course of this study.

“I appreciated the opportunity to present on the promising results of Nanoscope’s Phase 2 STARLIGHT clinical trial. With no current treatment options, MCO-010 may bring hope to those patients with severe vision loss due to Stargardt disease by restoring broadband light sensitivity,” said Dr. Allen Ho, Professor of Ophthalmology at Thomas Jefferson University and Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital.

“We are thrilled to have had Dr. Allen Ho present the Phase 2 STARLIGHT clinical trial data at this year’s ASRS. MCO-010 is advancing our proprietary AAV gene therapy platform with the potential to improve vision for patients with Stargardt disease and other inherited retinal diseases (IRDs). These results offer promising prospects for addressing this challenging disease,” said Sulagna Bhattacharya, Chief Executive Officer & Co-Founder of Nanoscope.